Ibrance Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Ibrance (palbociclib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Ibrance is used in men and women to treat HR-positive, HER2-negative breast cancer that has spread to other parts of the body. In postmenopausal women, Ibrance is given in combination with a hormonal medicine such as letrozole (Femara). In others, Ibrance is given together with fulvestrant (Faslodex).https://www.drugs.com/ibrance.html